CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) shares were down 3% during trading on Thursday . The stock traded as low as $0.3039 and last traded at $0.32. Approximately 2,005,361 shares traded hands during trading, a decline of 2% from the average daily volume of 2,040,910 shares. The stock had previously closed at $0.33.
CytoDyn Price Performance
The company has a market cap of $405.07 million, a PE ratio of -32.00 and a beta of 1.33. The stock has a 50 day simple moving average of $0.27 and a two-hundred day simple moving average of $0.30.
About CytoDyn
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Recommended Stories
- Five stocks we like better than CytoDyn
- 5 discounted opportunities for dividend growth investors
- The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
- Earnings Per Share Calculator: How to Calculate EPS
- Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF
- Top Stocks Investing in 5G Technology
- Strong Quarter, Weak Reaction: Why GitLab Shares Dropped
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
